• <nav id="08sis"></nav>
  • <menu id="08sis"><strong id="08sis"></strong></menu>
  • <menu id="08sis"><nav id="08sis"></nav></menu>
  • <dd id="08sis"></dd>
  • <menu id="08sis"></menu>
  •  
     
    Company News 
    Corporate?Activities 
    Industry?News 
    Contact: Mr Gerry
    Tel: 86-21-61900721
                      61900733
    Fax: 86-21-61900735
    Mobile: 86-13636696795
    E-mail: sales@run-biotech.com
    Website: www.cnhbian.com

    FDA OK's Monthly Schizophrenia Drug
    Shanghai Run-Biotech Co.,Ltd.   2013-04-12 00:09:27 Author:By Caroline Cassels Source:Medscape Medical News Font size:[Large][Middle][Small]

    March 1, 2013 -- The FDA has approved a long-acting version of the antipsychotic drug Abilify to treat adults with schizophrenia.

    Abilify Maintena is a freeze-dried powder reconstituted with water to form an extended-release medication that can be injected once a month, according to the manufacturers, Otsuka and Lundbeck A/S. The current version of Abilify is taken by mouth daily.

    The FDA approval follows positive results of a recent study showing that adults who got the injections had a greater delay in time to relapse and a lower rate of relapse compared with adults who received a placebo.

    "Protection from relapse of schizophrenia is important for patients, their families, and the communities in which they live," researcher John M. Kane, MD, chair of psychiatry at the Zucker Hillside Hospital in Glen Oaks, N.Y.,  says in a company release.

    "As a strong believer in long-acting therapies for schizophrenia, I think it is important for physicians to have a new and effective once-monthly treatment option that can help reduce the risk of relapse and manage symptoms in patients," he says.

    Because of an increased risk of harm or death associated with antipsychotic use in the elderly, the company notes that this drug should not be used in elderly patients with dementia-related psychosis.

    The medication also should not be given to people with a known hypersensitivity reaction to Abilify.

    To see a version of this story for physicians, visit Medscape, the leading site for physicians and health care professionals.

    About us Projects Services News Client Support
    Our Team
    R & D Capabilities
    Enterprise Culture
     

    Pharmaceutical Discovery
    bio-pharmaceuticals
    Biological Reagents
    Analysis & Separation
    Natural Healthcare
    Standard Sample
    Process Development
    Preclinical Research

     
    Company News
    Corporate Activities
    Industry News
     
    Download
    Login
    Feedback
    Contact us
    Job

    Shanghai Run-Biotech Co.,Ltd. Copyright ? 2013

    module not exist 久碰香蕉线视频在线观看视频_日韩10000免费拍拍拍_中国一级牲交作爱片免费观看_四库影院永久国产精品 <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <文本链> <文本链> <文本链> <文本链> <文本链> <文本链>